Fidelio Capital acquires Premune’s shares in Nextmune

December 15, 2020

We are pleased to announce that, effective 24 November 2020, Fidelio Capital AB (“Fidelio”) has completed the acquisition of Premune AB’s (“Premune”) shares in Nextmune. Through the transaction, Fidelio will increase its ownership in Nextmune and become the majority owner. Nextmune is a leading company within specialty pharmaceuticals for companion animals with sales in over 75 markets worldwide.

With Fidelio as the majority owner, Nextmune will have the support and resources to continue to invest in innovation and R&D and to broaden its product portfolio. The transaction will not lead to any operational changes in the company, which will continue to run in the same way as today.

Fidelio looks forward to continuing to support Nextmune on its journey to improve the quality of life for companion animals around the world.

Recent news

Interview with Patrik Eriksson, CEO Vimian

Vimian’s new CEO reflects on the evolution of animal health and the thrills of a global journey Amidst a rapidly expanding animal health sector, Patrik Eriksson, the new CEO at Vimian, discusses the company’s strategic direction and his enthusiasm for

Read more

Vimian resolves on a rights issue of up to approx…

The Board of Directors of Vimian Group AB has based on the authorisation from the Annual General Meeting on 2 June 2023, resolved on a rights issue of up to approximately SEK 1,633 million. The purpose of the Rights Issue

Read more

David von Laskowski, Greenfood’s CEO, is awarde…

On the 22 of February, the winners of the “CEO of the Year” award were announced at Kistamässan in Stockholm. The winner in the Large-Cap category was David von Laskowski, Picadeli & Greenfood Group. “CEO of the Year” has been

Read more